Disease management programs for patients with COPD in Germany: A longitudinal evaluation of routinely collected patient records

Respiratory Care

Volumn 59, Issue 7, 2014, Pages 1123-1132

  Mehring, Michael ^a   Donnachie, Ewan ^b   Fexer, Johannes ^a   Hofmann, Frank ^b   Schneider, Antonius ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b National Association of Statutory Health Insurance Physicians of Bavaria   (Germany)

Author keywords

Active patient participation; COPD; Disease management program; Emergency admission; Exacerbations; General practice; Guideline adherence; Pharmacotherapy

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; THEOPHYLLINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; FEMALE; GERMANY; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH PROGRAM; HOSPITAL ADMISSION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; PATIENT CARE; PATIENT EDUCATION; POPULATION BASED CASE CONTROL STUDY; PRACTICE GUIDELINE; SMOKING; STATISTICAL PARAMETERS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; COMPLICATION; DISEASE MANAGEMENT; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; PATHOPHYSIOLOGY; PROGRAM EVALUATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDY; SELF CARE;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DISEASE MANAGEMENT; FEMALE; FORCED EXPIRATORY VOLUME; GERMANY; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PROGRAM EVALUATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SELF CARE; YOUNG ADULT;

EID: 84925381274     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.02748     Document Type: Article

References (39)

1. van Lente EJ. Erfahrungen mit strukturierten Behandlungsprogram-men (DMPs) in Deutschland. In: Schwerpunkt: Chronische Er-krankungen: 79 Tabellen. Stuttgart: Schattauer; 2010: 55-83.
2. Stock S, Drabik A, Büscher G, Graf C, Ullrich W, Gerber A, et al. German diabetes management programs improve quality of care and curb costs. Health Aff (Millwood) 2010; 29(12): 2197-2205.
3. Miksch A, Laux G, Ose D, Joos S, Campbell S, Riens B, et al. Is there a survival benefit within a German primary care-based disease management program? Am J Manag Care 2010; 16(1): 49-54.
4. Stark RG, Schunk MV, Meisinger C, Rathmann W, Leidl R, Holle R. Medical care of type 2 diabetes in German disease management programmes: a population-based evaluation. Diabetes Metab Res Rev 2011; 27(4): 383-391.
5. Leinert J, Riedel W. Ergebnisse der AOK bundesauswertung zur gesetzlichen Evaluation der deutschen Disease Management Programme. Available at https://www. aok-gesundheitspartner. de/impe-ria/md/gpp/bund/dmp/evaluation/konferenz_juni09/dmp_konf29_30_06_09_infas. pdf. Accessed on June 18, 2013.
6. Mehring M, Donnachie E, Mutschler R, Hofmann F, Keller M, Schneider A. Disease management programs for patients with asthma in Germany: a longitudinal population-based study. Respir Care 2013; 58(7): 1170-1177.
7. Ofman JJ, Badamgarav E, Henning JM, Knight K, Gano AD, Levan RK, et al. Does disease management improve clinical and economic outcomes in patients with chronic diseases? A systematic review. Am J Med 2004; 117(3): 182-192.
8. Tsai AC, Morton SC, Mangione CM, Keeler EB. A meta-analysis of interventions to improve care for chronic illnesses. Am J Manag Care 2005; 11(8): 478-488.
9. Ouwens M, Wollersheim H, Hermens R. Hulscher M, Grol R. Integrated care programmes for chronically ill patients: a review of systematic reviews. Int J Qual Health Care 2005; 17(2): 141-146.
10. Solberg LI, Brekke ML, Fazio CJ, Fowles J, Jacobsen DN, Kottke TE, et al. Lessons from experienced guideline implementers: attend to many factors and use multiple strategies. Jt Comm J Qual Improv 2000; 26(4): 171-188.
11. Grimshaw JM, Shirran L, Thomas R, Mowatt G, Fraser C, Bero L et al. Changing provider behavior: an overview of systematic reviews of interventions. Med Care 2001; 39(8 Suppl 2): 112-1145.
12. Adams SG, Smith PK, Allan PF, Anzueto A, Pugh JA, Cornell JE. Systematic review of the chronic care model in chronic obstructive pulmonary disease prevention and management. Arch Intern Med 2007; 167(6): 551-561.
13. Taylor SJC, Candy B, Bryar RM, Ramsay J, Vrijhoef HJM, Esmond G, et al. Effectiveness of innovations in nurse led chronic disease management for patients with chronic obstructive pulmonary disease: systematic review of evidence. BMJ 2005; 331 (7515): 485.
14. Rice KL, Dewan N, Bloomfield HE, Grill J, Schult TM, Nelson DB et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2010; 182(7): 890-896.
15. Steuten L, Vrijhoef B. van Merode F, Wesseling G, Spreeuwenberg C. Evaluation of a regional disease management programme for patients with asthma or chronic obstructive pulmonary disease. Int J Qual Health Care 2006; 18(6): 429-436.
16. Monninkhof E, van der Valk P. van der Palen J, van Herwaarden C, Partridge MR, Zielhuis G. Self-management education for patients with chronic obstructive pulmonary disease: a systematic review. Thorax 2003; 58(5): 394-398.
17. Walters JA, Turnock AC, Walters EH, Wood-Baker R. Action plans with limited patient education only for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010; (5): CD005074.
18. Lauterbach KW. Disease management in Deutschland: Vorausset-zungen, Rahmenbedingungen, Faktoren zur Entwicklung, Implemen-tierung und Evaluation. Gutachten im Auftrag des Verbandes der Angestellten-Krankenkassen e. V. (VdAK) und des Arbeiter-Ersatz-kassen-Verbandes e. V. (AEV) 2001 [Internet]. Available at http://www. gesundheitspolitik. org/01_gesundheitssystem/disease-management/allgemeine-infos/DMP_Gutachten_Lauterbach. pdf. Accessed on June 18, 2013.
19. Advisory Council for the Concerted Action in Health Care. Appropriateness and efficiency Volume III: overuse, underuse and misuse. 2001 [Internet], http://www. svr-gesundheit. de/fileadmin/user_upload/Gutachten/2000-2001/Kurzf-engl01. pdf. Accessed on June 18, 2013.
20. Bundesärztekammer (BÄK) KB (AWMF). Nationale Versorgung-sLeitlinie COPD: Langfassung. 1. Auflage, Version 1. 9, 01/2012. Available at http://www. versorgungsleitlinien. de/themen/copd/pdf/nvl-copd-lang-L9. pdf. Accessed on June 18, 2013.
21. Robins JM, Rotnitzky A, Zhao LP. Analysis of semiparametric regression models for repeated outcomes in the presence of missing data. J Am Stat Assoc 1995; 90(429): 106-121.
22. Hogan JW, Roy J, Korkontzelou C. Handling drop-out in longitudinal studies. Stat Med 2004; 23(9): 1455-1497.
23. Fitzmaurice G, Davidian M, Verbeke G, Molenberghs G. Longitudinal data analysis. Boca Raton, FL: CRC Press; 2008: 453-476.
24. R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria. 2011 [Internet], Available at http://www. R-project. org/. Accessed on June 18, 2013.
25. Au DH, Bryson CL, Chien JW, Sun H, Udris EM, Evans LE et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. J Gen Intern Med 2009; 24(4): 457-463.
26. Kaper J, Wagena EJ, Willemsen MC, van Schayck CP. Reimbursement for smoking cessation treatment may double the abstinence rate: results of a randomized trial. Addiction 2005; 100(7): 1012-1020.
27. Kaper J, Wagena EJ, Willemsen MC, van Schayck CP. A randomized controlled trial to assess the effects of reimbursing the costs of smoking cessation therapy on sustained abstinence. Addiction 2006; 101(11): 1656-1661.
28. Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prütz C et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96(9): 700-708.
29. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157(5 Pt 1): 1418-1422.
30. Bourbeau J, Ford G, Zackon H, Pinsky N, Lee J, Ruberto G. Impact on patients' health status following early identification of a COPD exacerbation. Eur Respir J 2007; 30(5): 907-913.
31. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57(10): 847-852.
32. Soler-Cataluña JJ, Martínez-García MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60(11): 925-931.
33. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161 (5): 1608-1613.
34. Camargo CA, Ginde AA, Clark S, Cartwright CP, Falsey AR, Niewoehner DE. Viral pathogens in acute exacerbations of chronic obstructive pulmonary disease. Intern Emerg Med 2008; 3(4): 355-359.
35. Wilkinson TMA, Donaldson GC, Hurst JR, Seemungal TAR, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169(12): 1298-1303.
36. Niewoehner DE, Lokhnygina Y, Rice K, Kuschner WG, Sharafkhaneh A, Sarosi GA et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007; 131 (1): 20-28.
37. Lemmens KMM, Nieboer AP, Huijsman R. A systematic review of integrated use of disease-management interventions in asthma and COPD. Respir Med 2009; 103(5): 670-691.
38. Moullec G, Lavoie KL, Rabhi K, Julien M, Favreau H, Labrecque M. Effect of an integrated care programme on re-hospitalization of patients with chronic obstructive pulmonary disease. Respirology 2012; 17(4): 707-714.
39. Wegscheider K. DMP: Methodik fiir faire Vergleiche. Monitor Ver-sorgungsforschung 2011; 4(1): 25-27. Article in German.